中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
Chinese Journal of Osteoporosis
2015年
8期
986-989
,共4页
绝经后骨质疏松症%骨关节炎%唑来膦酸%骨密度%生活质量
絕經後骨質疏鬆癥%骨關節炎%唑來膦痠%骨密度%生活質量
절경후골질소송증%골관절염%서래련산%골밀도%생활질량
Postmenopausal osteoporosis%Osteoarthritis%Zoledronic acid%Bone mineral density%Quality of life
目的 探讨唑来膦酸对合并骨关节炎的绝经后骨质疏松症( Postmenopuasal osteoporosis,PMOP)患者的影响. 方法 选取我院2010年2月至2014年5月收治的98例合并骨关节炎的绝经后骨质疏松症患者为研究对象,采用随机数字表法分为观察组和对照组各49例,对照组予以钙剂(碳酸钙D3 片600 mg qd)、活性维生素D(阿法骨化醇软胶囊0.25 ug qd)基础补充治疗,同时予以玻璃酸钠25 mg qw关节腔内注射治疗;观察组在上述药物治疗基础上联合唑来膦酸5 mg一年一次静脉滴注治疗. 研究比较两组治疗前后膝关节功能lysholm评分、疼痛VAS评分、生活质量评分( SF-36 )以及腰椎及股骨的骨密度变化. 结果 Lysholm与VAS评分:治疗6、12个月后,观察组膝关节功能lysholm评分显著高于对照组,VAS评分显著低于对照组(P<0.05);骨密度:治疗6、12个月后,观察组L1-L4、Ward's三角、股骨颈、股骨Troch等部位骨密度显著高于对照组(P<0.05);生活质量:观察组PF、RP、BP、GH、VT、SF、RE、MH、Total评分均显著高于对照组( P<0.05). 结论 唑来膦酸有助于缓解合并骨关节炎的绝经后骨质疏松症患者疼痛程度,增加骨密度,改善膝关节功能,提高生活质量.
目的 探討唑來膦痠對閤併骨關節炎的絕經後骨質疏鬆癥( Postmenopuasal osteoporosis,PMOP)患者的影響. 方法 選取我院2010年2月至2014年5月收治的98例閤併骨關節炎的絕經後骨質疏鬆癥患者為研究對象,採用隨機數字錶法分為觀察組和對照組各49例,對照組予以鈣劑(碳痠鈣D3 片600 mg qd)、活性維生素D(阿法骨化醇軟膠囊0.25 ug qd)基礎補充治療,同時予以玻璃痠鈉25 mg qw關節腔內註射治療;觀察組在上述藥物治療基礎上聯閤唑來膦痠5 mg一年一次靜脈滴註治療. 研究比較兩組治療前後膝關節功能lysholm評分、疼痛VAS評分、生活質量評分( SF-36 )以及腰椎及股骨的骨密度變化. 結果 Lysholm與VAS評分:治療6、12箇月後,觀察組膝關節功能lysholm評分顯著高于對照組,VAS評分顯著低于對照組(P<0.05);骨密度:治療6、12箇月後,觀察組L1-L4、Ward's三角、股骨頸、股骨Troch等部位骨密度顯著高于對照組(P<0.05);生活質量:觀察組PF、RP、BP、GH、VT、SF、RE、MH、Total評分均顯著高于對照組( P<0.05). 結論 唑來膦痠有助于緩解閤併骨關節炎的絕經後骨質疏鬆癥患者疼痛程度,增加骨密度,改善膝關節功能,提高生活質量.
목적 탐토서래련산대합병골관절염적절경후골질소송증( Postmenopuasal osteoporosis,PMOP)환자적영향. 방법 선취아원2010년2월지2014년5월수치적98례합병골관절염적절경후골질소송증환자위연구대상,채용수궤수자표법분위관찰조화대조조각49례,대조조여이개제(탄산개D3 편600 mg qd)、활성유생소D(아법골화순연효낭0.25 ug qd)기출보충치료,동시여이파리산납25 mg qw관절강내주사치료;관찰조재상술약물치료기출상연합서래련산5 mg일년일차정맥적주치료. 연구비교량조치료전후슬관절공능lysholm평분、동통VAS평분、생활질량평분( SF-36 )이급요추급고골적골밀도변화. 결과 Lysholm여VAS평분:치료6、12개월후,관찰조슬관절공능lysholm평분현저고우대조조,VAS평분현저저우대조조(P<0.05);골밀도:치료6、12개월후,관찰조L1-L4、Ward's삼각、고골경、고골Troch등부위골밀도현저고우대조조(P<0.05);생활질량:관찰조PF、RP、BP、GH、VT、SF、RE、MH、Total평분균현저고우대조조( P<0.05). 결론 서래련산유조우완해합병골관절염적절경후골질소송증환자동통정도,증가골밀도,개선슬관절공능,제고생활질량.
Objective To study the effect of zoledronic acid on the treatment of postmenopausal osteoporosis ( PMOP) patients complicated with osteoarthritis.Methods Ninety-eight postmenopausal osteoporotic patients complicated with osteoarthritis in our hospital from February 2010 to May 2014 were selected.They were randomly divided into the observation group and the control group. There were 49 patients in each group.The patients in control group received oral calcium carbonate D3 600 mg and alfacalcidol soft capsules 0.25ug per day, and intra-articular injection of 25 mg sodium hyaluronate per week.In the treatment group, all the patients received intravenous injection of 5mg zoledronic acid once per year on the basis of the same treatment in the control group.The knee joint function (Lysholm score), pain (VAS score), life quality score (SF-36), and bone mineral density of the lumbar spine (L1-L4) , femoral neck, Ward' s triangle, and the Troch region were examined and compared between the two groups.Results Lysholm score was significantly higher in the observation group than in control group, but VAS score was significantly lower than in control group after 6-and 12-month treatment (P<0.05).Bone mineral density of the L1-L4, Ward's triangle, femoral neck, and Troch in the observation group was significantly higher than that in the control group ( P<0.05) .The life quality evaluation showed that PF, RP, BP, GH, VT, SF, RE, MH, and total scores in the treatment group were significantly higher than those in the control group ( P<0.05).Conclusion Zoledronic acid is beneficial in releasing the pain in PMOP patients complicated with osteoarthritis.It can also increase bone mineral density, improve knee joint function, and improve the life quality.
